Product Details for NDA 021342
LEVO-T (LEVOTHYROXINE SODIUM)
0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Marketing Status: Prescription
0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Marketing Status: Prescription
0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Marketing Status: Prescription
0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Marketing Status: Prescription
0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Marketing Status: Prescription
0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Marketing Status: Prescription
0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Marketing Status: Prescription
0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Marketing Status: Prescription
0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Marketing Status: Prescription
0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Marketing Status: Prescription
0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Marketing Status: Prescription
0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Marketing Status: Prescription
0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Marketing Status: Prescription
Active Ingredient: LEVOTHYROXINE SODIUM
Proprietary Name: LEVO-T
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Reference Listed Drug: No
Reference Standard: No
TE Code: AB1,AB2,AB3
Application Number: N021342
Product Number: 001
Approval Date: Mar 1, 2002
Applicant Holder Full Name: CEDIPROF INC
Marketing Status: Prescription
Patent and Exclusivity Information
LEVO-T (LEVOTHYROXINE SODIUM)
Proprietary Name: LEVO-T
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Reference Listed Drug: No
Reference Standard: No
TE Code: AB1,AB2,AB3
Application Number: N021342
Product Number: 001
Approval Date: Mar 1, 2002
Applicant Holder Full Name: CEDIPROF INC
Marketing Status: Prescription
Patent and Exclusivity Information
0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Marketing Status: Prescription
Active Ingredient: LEVOTHYROXINE SODIUM
Proprietary Name: LEVO-T
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Reference Listed Drug: No
Reference Standard: No
TE Code: AB1,AB2,AB3
Application Number: N021342
Product Number: 002
Approval Date: Mar 1, 2002
Applicant Holder Full Name: CEDIPROF INC
Marketing Status: Prescription
Patent and Exclusivity Information
LEVO-T (LEVOTHYROXINE SODIUM)
Proprietary Name: LEVO-T
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Reference Listed Drug: No
Reference Standard: No
TE Code: AB1,AB2,AB3
Application Number: N021342
Product Number: 002
Approval Date: Mar 1, 2002
Applicant Holder Full Name: CEDIPROF INC
Marketing Status: Prescription
Patent and Exclusivity Information
0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Marketing Status: Prescription
Active Ingredient: LEVOTHYROXINE SODIUM
Proprietary Name: LEVO-T
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Reference Listed Drug: No
Reference Standard: No
TE Code: AB1,AB2,AB3
Application Number: N021342
Product Number: 003
Approval Date: Mar 1, 2002
Applicant Holder Full Name: CEDIPROF INC
Marketing Status: Prescription
Patent and Exclusivity Information
LEVO-T (LEVOTHYROXINE SODIUM)
Proprietary Name: LEVO-T
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Reference Listed Drug: No
Reference Standard: No
TE Code: AB1,AB2,AB3
Application Number: N021342
Product Number: 003
Approval Date: Mar 1, 2002
Applicant Holder Full Name: CEDIPROF INC
Marketing Status: Prescription
Patent and Exclusivity Information
0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Marketing Status: Prescription
Active Ingredient: LEVOTHYROXINE SODIUM
Proprietary Name: LEVO-T
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Reference Listed Drug: No
Reference Standard: No
TE Code: AB1,AB2,AB3
Application Number: N021342
Product Number: 004
Approval Date: Mar 1, 2002
Applicant Holder Full Name: CEDIPROF INC
Marketing Status: Prescription
Patent and Exclusivity Information
LEVO-T (LEVOTHYROXINE SODIUM)
Proprietary Name: LEVO-T
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Reference Listed Drug: No
Reference Standard: No
TE Code: AB1,AB2,AB3
Application Number: N021342
Product Number: 004
Approval Date: Mar 1, 2002
Applicant Holder Full Name: CEDIPROF INC
Marketing Status: Prescription
Patent and Exclusivity Information
0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Marketing Status: Prescription
Active Ingredient: LEVOTHYROXINE SODIUM
Proprietary Name: LEVO-T
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Reference Listed Drug: No
Reference Standard: No
TE Code: AB1,AB2,AB3
Application Number: N021342
Product Number: 005
Approval Date: Mar 1, 2002
Applicant Holder Full Name: CEDIPROF INC
Marketing Status: Prescription
Patent and Exclusivity Information
LEVO-T (LEVOTHYROXINE SODIUM)
Proprietary Name: LEVO-T
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Reference Listed Drug: No
Reference Standard: No
TE Code: AB1,AB2,AB3
Application Number: N021342
Product Number: 005
Approval Date: Mar 1, 2002
Applicant Holder Full Name: CEDIPROF INC
Marketing Status: Prescription
Patent and Exclusivity Information
0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Marketing Status: Prescription
Active Ingredient: LEVOTHYROXINE SODIUM
Proprietary Name: LEVO-T
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Reference Listed Drug: No
Reference Standard: No
TE Code: AB1,AB2,AB3
Application Number: N021342
Product Number: 006
Approval Date: Mar 1, 2002
Applicant Holder Full Name: CEDIPROF INC
Marketing Status: Prescription
Patent and Exclusivity Information
LEVO-T (LEVOTHYROXINE SODIUM)
Proprietary Name: LEVO-T
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Reference Listed Drug: No
Reference Standard: No
TE Code: AB1,AB2,AB3
Application Number: N021342
Product Number: 006
Approval Date: Mar 1, 2002
Applicant Holder Full Name: CEDIPROF INC
Marketing Status: Prescription
Patent and Exclusivity Information
0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Marketing Status: Prescription
Active Ingredient: LEVOTHYROXINE SODIUM
Proprietary Name: LEVO-T
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Reference Listed Drug: No
Reference Standard: No
TE Code: AB1,AB2,AB3
Application Number: N021342
Product Number: 007
Approval Date: Mar 1, 2002
Applicant Holder Full Name: CEDIPROF INC
Marketing Status: Prescription
Patent and Exclusivity Information
LEVO-T (LEVOTHYROXINE SODIUM)
Proprietary Name: LEVO-T
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Reference Listed Drug: No
Reference Standard: No
TE Code: AB1,AB2,AB3
Application Number: N021342
Product Number: 007
Approval Date: Mar 1, 2002
Applicant Holder Full Name: CEDIPROF INC
Marketing Status: Prescription
Patent and Exclusivity Information
0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Marketing Status: Prescription
Active Ingredient: LEVOTHYROXINE SODIUM
Proprietary Name: LEVO-T
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Reference Listed Drug: No
Reference Standard: No
TE Code: AB1,AB2,AB3
Application Number: N021342
Product Number: 012
Approval Date: Dec 8, 2003
Applicant Holder Full Name: CEDIPROF INC
Marketing Status: Prescription
Patent and Exclusivity Information
LEVO-T (LEVOTHYROXINE SODIUM)
Proprietary Name: LEVO-T
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Reference Listed Drug: No
Reference Standard: No
TE Code: AB1,AB2,AB3
Application Number: N021342
Product Number: 012
Approval Date: Dec 8, 2003
Applicant Holder Full Name: CEDIPROF INC
Marketing Status: Prescription
Patent and Exclusivity Information
0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Marketing Status: Prescription
Active Ingredient: LEVOTHYROXINE SODIUM
Proprietary Name: LEVO-T
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Reference Listed Drug: No
Reference Standard: No
TE Code: AB1,AB2,AB3
Application Number: N021342
Product Number: 008
Approval Date: Mar 1, 2002
Applicant Holder Full Name: CEDIPROF INC
Marketing Status: Prescription
Patent and Exclusivity Information
LEVO-T (LEVOTHYROXINE SODIUM)
Proprietary Name: LEVO-T
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Reference Listed Drug: No
Reference Standard: No
TE Code: AB1,AB2,AB3
Application Number: N021342
Product Number: 008
Approval Date: Mar 1, 2002
Applicant Holder Full Name: CEDIPROF INC
Marketing Status: Prescription
Patent and Exclusivity Information
0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Marketing Status: Prescription
Active Ingredient: LEVOTHYROXINE SODIUM
Proprietary Name: LEVO-T
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Reference Listed Drug: No
Reference Standard: No
TE Code: AB1,AB2,AB3
Application Number: N021342
Product Number: 009
Approval Date: Mar 1, 2002
Applicant Holder Full Name: CEDIPROF INC
Marketing Status: Prescription
Patent and Exclusivity Information
LEVO-T (LEVOTHYROXINE SODIUM)
Proprietary Name: LEVO-T
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Reference Listed Drug: No
Reference Standard: No
TE Code: AB1,AB2,AB3
Application Number: N021342
Product Number: 009
Approval Date: Mar 1, 2002
Applicant Holder Full Name: CEDIPROF INC
Marketing Status: Prescription
Patent and Exclusivity Information
0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Marketing Status: Prescription
Active Ingredient: LEVOTHYROXINE SODIUM
Proprietary Name: LEVO-T
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Reference Listed Drug: No
Reference Standard: No
TE Code: AB1,AB2,AB3
Application Number: N021342
Product Number: 010
Approval Date: Mar 1, 2002
Applicant Holder Full Name: CEDIPROF INC
Marketing Status: Prescription
Patent and Exclusivity Information
LEVO-T (LEVOTHYROXINE SODIUM)
Proprietary Name: LEVO-T
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Reference Listed Drug: No
Reference Standard: No
TE Code: AB1,AB2,AB3
Application Number: N021342
Product Number: 010
Approval Date: Mar 1, 2002
Applicant Holder Full Name: CEDIPROF INC
Marketing Status: Prescription
Patent and Exclusivity Information
0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Marketing Status: Prescription
Active Ingredient: LEVOTHYROXINE SODIUM
Proprietary Name: LEVO-T
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Reference Listed Drug: No
Reference Standard: No
TE Code: AB1,AB2,AB3
Application Number: N021342
Product Number: 011
Approval Date: Mar 1, 2002
Applicant Holder Full Name: CEDIPROF INC
Marketing Status: Prescription
Patent and Exclusivity Information
Proprietary Name: LEVO-T
Dosage Form; Route of Administration: TABLET; ORAL
Strength: 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
Reference Listed Drug: No
Reference Standard: No
TE Code: AB1,AB2,AB3
Application Number: N021342
Product Number: 011
Approval Date: Mar 1, 2002
Applicant Holder Full Name: CEDIPROF INC
Marketing Status: Prescription
Patent and Exclusivity Information